Innovation & intellectual property · 05/10/2020Updated: 10/17/2026 · 1 min read
U.S. Patent Office Grants Interim Extension to Vernakalant Hydrochloride Patent
Summary
The U.S. Patent and Trademark Office has issued a one-year extension to the term of U.S. Patent No. 7,524,879, which covers Vernakalant Hydrochloride, a medication used to treat certain heart rhythm disorders.
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →